465 related articles for article (PubMed ID: 30543010)
21. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
22. Trends In Orphan New Molecular Entities, 1983-2014: Half Were First In Class, And Rare Cancers Were The Most Frequent Target.
Miller KL; Lanthier M
Health Aff (Millwood); 2016 Mar; 35(3):464-70. PubMed ID: 26953301
[TBL] [Abstract][Full Text] [Related]
23. Delayed access to treatments for rare diseases: who's to blame?
Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
[TBL] [Abstract][Full Text] [Related]
25. Orphan Medicines for Pediatric Use: A Focus on the European Union.
Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
[TBL] [Abstract][Full Text] [Related]
26. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
27. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
28. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
29. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
30. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
31. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
32. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
33. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
[TBL] [Abstract][Full Text] [Related]
34. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
Guan X; Zhang J; Man C; Ni B; Shi L
J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
[TBL] [Abstract][Full Text] [Related]
35. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
36. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
37. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
38. Assessing the economic challenges posed by orphan drugs.
Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
[TBL] [Abstract][Full Text] [Related]
39. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
40. Legal and regulatory aspects of orphan drugs.
Shani S; Yahalom Z
Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
